Biosimilars for Retinal Diseases: An Update

被引：29
|
作者：
Sharma, Ashish [1 ]
Kumar, Nilesh [1 ]
Parachuri, Nikulaa [1 ]
Bandello, Francesco [2 ]
Kuppermann, Baruch D. [3 ]
Loewenstein, Anat [4 ]
机构：
[1] Lotus Eye Hosp & Inst, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India
[2] Univ Vita Salute, Sci Inst San Raffaele, Milan, Italy
[3] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA
[4] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel
来源：
AMERICAN JOURNAL OF OPHTHALMOLOGY | 2021年 / 224卷
关键词：
MACULAR DEGENERATION; RANIBIZUMAB; THERAPY;
D O I：
10.1016/j.ajo.2020.11.017
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
endothelial growth factor agents for retinal diseases and provide an update about their development. ? DESIGN: Literature review. ? METHODS: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. ? RESULTS: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. ? CONCLUSION: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions. (Am J Ophthalmol 2021;224:36?42. ? 2020 Elsevier Inc. All rights reserved.)
引用
收藏
页码：36 / 42
页数：7
相关论文
共 50 条
  • [41] Overview of Biosimilars in Inflammatory Bowel Diseases
    Feagins, Linda A.
    Gold, Stephanie
    Steinlauf, Adam F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (02): : 229 - 232
  • [42] The role of biosimilars in the treatment of rheumatic diseases
    Doerner, Thomas
    Strand, Vibeke
    Castaneda-Hernandez, Gilberto
    Ferraccioli, Gianfranco
    Isaacs, John D.
    Kvien, Tore K.
    Martin-Mola, Emilio
    Mittendorf, Thomas
    Smolen, Josef S.
    Burmester, Gerd R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (03) : 322 - 328
  • [43] Biosimilars in the therapy of inflammatory bowel diseases
    Hlavaty, Tibor
    Letkovsky, Juraj
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 581 - 587
  • [44] The Experience with Biosimilars of Infliximab in Rheumatic Diseases
    Azevedo, Valderilio Feijo
    Kos, Igor Age
    Ariello, Leonardo
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (44) : 6752 - 6758
  • [45] Biosimilars in the Treatment of Retinal Disease in the United States
    Vakharia, Priya S.
    Eichenbaum, David A.
    Baumal, Caroline R.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2023, 54 (06): : 362 - 366
  • [46] Neufassung der Stellungnahme der DGRh zu Biosimilars – Update 2017Revised version of the statement by the DGRh on biosimilars—update 2017
    J. Braun
    H. M. Lorenz
    U. Müller-Ladner
    M. Schneider
    H. Schulze-Koops
    Ch. Specker
    A. Strangfeld
    U. Wagner
    T. Dörner
    Zeitschrift für Rheumatologie, 2018, 77 : 81 - 90
  • [47] Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
    Igoe, Jane M.
    Lam, Byron L.
    Gregori, Ninel Z.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [48] Revised Version of the Statement by the DGRh on Biosimilars - Update 2017
    Braun, J.
    Lorenz, H. M.
    Mueller-Ladner, U.
    Schneider, M.
    Schulze-Koops, H.
    Specker, Ch.
    Strangfeld, A.
    Wagner, U.
    Doerner, T.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (01): : 81 - 90
  • [49] Regulatory challenges with biosimilars: an update from 20 countries
    Kang, Hye-Na
    Thorpe, Robin
    Knezevic, Ivana
    Casas Levano, Mary
    Chilufya, Mumbi Bernice
    Chirachanakul, Parichard
    Chua, Hui Ming
    Dalili, Dina
    Foo, Freddie
    Gao, Kai
    Habahbeh, Suna
    Hamel, Hugo
    Kim, Gi Hyun
    Perez Rodriguez, Violeta
    Putri, Desi Eka
    Rodgers, Jacqueline
    Savkina, Maria
    Semeniuk, Oleh
    Srivastava, Shraddha
    Tavares Neto, Joao
    Wadhwa, Meenu
    Yamaguchi, Teruhide
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2021, 1491 (01) : 42 - 59
  • [50] Food and Drug Administration guidances on biosimilars: an update for the gastroenterologist
    Epstein, Michael
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
12345